Could a simpler drug schedule improve multiple myeloma treatment?

This study tests a less intense version of a standard four-drug combination (Dara-RVd) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if giving one of the drugs (bortezomib) once a week instead of twice a week still works well while causing fewer side effects like nerve damage. About 39 adults will take part, and the main measure of success is whether the cancer becomes undetectable in the bone marrow.